C-X-C motif chemokine receptor 4
C-X-C motif chemokine receptor 4 (CXCR4) is a cell-surface chemokine receptor in the protein family that mediates responses to the chemokine CXCL12 (also called stromal cell-derived factor 1).
C-X-C motif chemokine receptor 4 (CXCR4) is a cell-surface chemokine receptor in the protein family that mediates responses to the chemokine CXCL12 (also called stromal cell-derived factor 1). It is best known for its role in directing cell migration, retention, and positioning within tissue microenvironments, especially in hematopoietic and immune contexts. Through CXCL12-CXCR4 signaling, cells can be anchored within protective niches, a mechanism that is biologically important in normal tissue homeostasis and is frequently co-opted in disease.
In medicine, CXCR4 is widely studied as a target in cancer, inflammatory disease, and drug-delivery strategies because it can influence tumor microenvironment interactions, immune-cell trafficking, and metastatic spread. In hematologic malignancies, CXCR4-mediated retention in the bone marrow microenvironment can support leukemia cell survival and chemoresistance. In solid tumors and inflammatory settings, CXCR4 expression on malignant cells, tumor-associated macrophages, or aged neutrophils has been linked to disease progression, immune remodeling, and tissue inflammation. These properties have made CXCR4 a recurring target for therapeutic inhibition, targeted nanomedicine, and molecular design efforts.
Where the papers sit
11 papers from the last 6 months study C-X-C motif chemokine receptor 4 directly · updated from PubMed 9 Nov 2026
Study type 0 clinical trials · 1 human data · 9 preclinical · 1 unclassified
Themes 3 themes · 1 new direction
-
Fibrosis and Leukemia Therapies
Fibrosis and myeloid leukemia are being approached with CXCR4 antagonism, siRNA delivery and pathway-directed combination therapy. AMD3100 or plerixafor-based strategies aim to remodel fibrotic niches or sensitize AML, including through AML1-ETO depletion and homoharringtonine sensitization. METTL1/m7G targeting broadens the leukemia focus beyond CXCR4, while senescence induction adds a separate antifibrotic route. Evidence remains preclinical, with efficacy and mechanism rather than clinical outcomes as the recurring endpoints.
5 papers · 45.5%
-
Neutrophil Extracellular Traps
Neutrophil extracellular traps are being positioned as a shared link between innate-cell aging and inflammatory disease. Aged-neutrophil accumulation is associated with intestinal inflammation in inflammatory bowel disease, while a NETs-related four-gene signature is proposed for abdominal aortic aneurysm diagnosis. The work moves from describing NET accumulation toward biomarker development, but the diagnostic signature still needs clinical validation. Mechanistic overlap is plausible, yet the disease settings and endpoints remain distinct.
2 papers · 18.2%
-
Others — CXCR4-Linked Disease Applications
Metastatic cancer is the main clinical focus, with CXCR4 signaling tied to invasion, migration and bone or cholangiocarcinoma spread. SULF2-YBX1-CXCR4 signaling appears as a mechanistic target, while neutrophil-inspired nanoparticles represent a therapeutic delivery strategy. Other work turns to small-molecule agonist design and 68Ga radiotracers for PET imaging, including atherosclerotic plaque. The cluster shares CXCR4-directed applications but not a single disease or developmental direction.
4 papers · 36.4%
CXCR4 is treated as a conformationally staged activation system for agonist design
The computational study of CXCR4 activation uses targeted and coarse-grained molecular-dynamics simulations to examine the receptor itself rather than its role as a disease-associated marker, signaling axis, or therapeutic target 42126261May. It finds that activation proceeds through three transition states, with ICL3 and transmembrane-helix rearrangements governing the highest barrier and specific W94 and E288 conformations lowering later barriers. This recasts CXCR4 as a structurally dynamic sequence of druggable activation states and provides a mechanistic basis for designing small-molecule agonists, a role not otherwise represented in the set.
Papers
The 11 papers from the last 6 months that study C-X-C motif chemokine receptor 4 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Fibrosis and Leukemia Therapies (5)
- CXCR4-targeted dual softener for inducing senescence therapy in hepatic fibrosis. Proceedings of the National Academy of Sciences of the United States of America · 17 Aug 2026 PMID 42607216
- Collagenase-Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis. Small (Weinheim an der Bergstrasse, Germany) · 3 Jul 2026 PMID 42396810
- Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia. Blood · 5 Jun 2026 PMID 42247311
- CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization. Materials today. Bio · 29 May 2026 PMID 42211065
- Multi-omics reveals a novel Cxcr4+ subpopulation of alveolar macrophages and therapeutic effect of AMD3100 in mice with advanced silicosis. Clinical and translational medicine · 28 May 2026 PMID 42204838
Neutrophil Extracellular Traps (2)
- Pathological accumulation of aged neutrophils contributes to intestinal inflammation in inflammatory bowel disease. Clinical science (London, England : 1979) · 1 Jun 2026 PMID 42222980
- Machine learning identifies a NETs-related four-gene diagnostic signature for abdominal aortic aneurysm. Medicine · 23 May 2026 PMID 42175497
Others — CXCR4-Linked Disease Applications (4)
- PMID 42126261
- SU056 potentiates SULF2 antibody in suppressing cholangiocarcinoma metastasis via SULF2-YBX1-CXCR4 signaling axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 12 Jun 2026 PMID 42284889
- Synthesis and Preclinical Evaluation of Structurally Optimized 68Ga-Labeled CXCR4 Radiotracers for PET Imaging of Atherosclerotic Plaque Inflammation. Journal of medicinal chemistry · 8 Jun 2026 PMID 42258221
- Neutrophil-lifecycle-inspired nanoplatform for the treatment of lung cancer bone metastasis. Nanoscale · 29 May 2026 PMID 42210861
By study type
Human data, design not indexed (1)
- Machine learning identifies a NETs-related four-gene diagnostic signature for abdominal aortic aneurysm. Medicine · 23 May 2026 PMID 42175497
Preclinical: animal, cell and lab studies (9)
- Engineered polymeric systems suppress breast cancer metastasis by manipulating the clustering states of cell surface C-X-C chemokine receptor 4. Journal of controlled release : official journal of the Controlled Release Society · 20 Sept 2026 PMID 42764094
- CXCR4-targeted dual softener for inducing senescence therapy in hepatic fibrosis. Proceedings of the National Academy of Sciences of the United States of America · 17 Aug 2026 PMID 42607216
- Collagenase-Coated Polymeric Drug/siRNA Nanoparticles Overcome ECM and Regulate Metabolic Reprogramming of Fibroblasts for Alleviating Pulmonary Fibrosis. Small (Weinheim an der Bergstrasse, Germany) · 3 Jul 2026 PMID 42396810
- SU056 potentiates SULF2 antibody in suppressing cholangiocarcinoma metastasis via SULF2-YBX1-CXCR4 signaling axis. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 12 Jun 2026 PMID 42284889
- Synthesis and Preclinical Evaluation of Structurally Optimized 68Ga-Labeled CXCR4 Radiotracers for PET Imaging of Atherosclerotic Plaque Inflammation. Journal of medicinal chemistry · 8 Jun 2026 PMID 42258221
- Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia. Blood · 5 Jun 2026 PMID 42247311
- Pathological accumulation of aged neutrophils contributes to intestinal inflammation in inflammatory bowel disease. Clinical science (London, England : 1979) · 1 Jun 2026 PMID 42222980
- Neutrophil-lifecycle-inspired nanoplatform for the treatment of lung cancer bone metastasis. Nanoscale · 29 May 2026 PMID 42210861
- Multi-omics reveals a novel Cxcr4+ subpopulation of alveolar macrophages and therapeutic effect of AMD3100 in mice with advanced silicosis. Clinical and translational medicine · 28 May 2026 PMID 42204838
Unclassified: not yet indexed with MeSH (1)
- CXCR4 antagonistic lipid nanoparticles loading siRNA combat refractory AML through AML1-ETO depletion and homoharringtonine sensitization. Materials today. Bio · 29 May 2026 PMID 42211065
Written from 11 PubMed abstracts, each one listed by PMID above. Published: 2026-07-30. Last written: 2026-08-26 by GPT. Drafted by language models from published abstracts; not medical advice.